China National Biotec Group Company Limited (CNBG) was first founded in 1919 as the Central Office of Epidemic Prevention. After the People’s Republic of China (PRC) was founded in 1949, it became administered by the Ministry of Public Health of the PRC. In 2010, the company was restructured as a subsidiary of China National Pharmaceutical Group Co., Ltd. (Sinopharm). At present, it has grown into a comprehensive biopharmaceutical company that integrates scientific research, production, sales, and postgraduate training. By the end of 2019, CNBG boasted 12 second-tier subsidiaries and 76 third- and lower-tier subsidiaries, with a total staff of 12,551 employees.

CNBG has diverse business segments covering six biopharmaceutical fields: human vaccines, blood products, medical aesthetics, animal health, antibodies and therapeutics, and medical diagnostics. It annually produces more than 700 million doses of 50 kinds of human vaccines, ranking the sixth in the world and supplying over 80 percent of vaccines for the National Immunization Program. With an annual plasma collection of more than 1,500 tons, CNBG produces 11 kinds of blood products. As the only botulinum toxin manufacturer approved by the Chinese government, CNBG’s own branded products are highly recognized by the medical aesthetics market. CNBG is also providing the society with all-round, high-quality services for animal vaccines and related veterinary biological products. It has developed a complete industrial chain for antibody drugs and a unique industrial chain for molecular diagnostic products.

Adhering to the philosophy of “All for Health, Health for All,” CNBG actively fulfills its social responsibility and has provided professional support for the country’s emergency responses to the outbreaks of major infectious diseases and epidemic prevention and control, as well as in disaster rescue and relief, which helped secure social stability. In the battle against the COVID-19 pandemic, CNBG has played an active role in scientific research, spearheading efforts from nucleic acid test kit development to the therapy of using plasma collected from recovered COVID-19 patients to treat the disease, and to obtaining certificate of approval for phase-3 clinical trials of an inactivated COVID-19 vaccine it developed. A series of major scientific research achievements have provided strong support for making the disease diagnosable, treatable and preventable.

Since the 13th Five-Year Plan began in 2016, CNBG has played a leading role in the industry and is striving to become a standard-setting innovative biopharmaceutical company with global competitiveness and respect.